| Oncologist (33) |  |
| Oncologist (33) | |
The researchers reported similar results in a study of breast cancer at the 2013 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
therapy alone according to a new study in the Journal of Clinical Oncology from Penn Medicine researchers.
#Radiation plus hormone therapy is such a treatment for men with aggressive prostate cancerssaid lead author Justin E. Bekelman MD an assistant professor of Radiation Oncology Medical Ethics and Health policy at Penn
Marginprobe was the subject of a major multi-institutional retrospective study led by Dr. Schnabel and published in the March 2014 edition in Annals of Surgical Oncology.
which has played a significant part in making this global effort a tremendous success. The main findings of the project COGS('Collaborative Oncological Gene-Environment Study')have been published in a special issue on genetic risk factors
In collaboration with Amato Giaccia professor of radiation oncology the researchers gave intravenous treatments of this bioengineered decoy protein to mice with aggressive breast and ovarian cancers.
Dr. Achilefu, who also happens to be co-leader of the Oncologic Imaging Program at Siteman Cancer Center,
director of urologic oncology at Columbia University Medical center. There are additional reasons, however, for high PSA levels
an oncologist at Pennsylvania State university in Hershey and lead author of the study, which is published today in Science Translational Medicine1.
says Andrew Thorburn, an oncologist at the University of Colorado Denver, who co-authored a review on the subject last year4."
"What needs to be done is to convince oncologists and cancer biologists that this new kind of immunotherapy can work,
Oncologist Renier Brentjens, also at Memorial Sloan-Kettering Cancer Center, remembers the day that he had to tell one of the patients in the trial that the weeks of high-dose chemotherapy the 58-year-old man had endured had worked not after all."
It also involved researchers from Karolinska Institutet Department of Oncology-Pathology, and Uppsala University. The study was financed with grants from several bodies,
This opens up a whole new field of being personalized able to do oncology where you can model human mutations
The research was funded by the Howard Hughes Medical Institute the Ludwig Center for Molecular Oncology at MIT and the National Cancer Institute u
The paper s other senior author is Brian Wolpin an assistant professor of medical oncology at Dana-Farber.
a professor of radiation oncology at Harvard Medical school and Massachusetts General Hospital. ur knowledge about the abundance of extracellular matrix proteins in tumors has been limited.
The research was funded by a National Science Foundation Graduate Research Fellowship a Mazumdar-Shaw International Oncology Fellowship the Ruth L. Kirschstein National Research Service Award from the National institutes of health
The research was funded by the Koch Institute Frontier Research Fund the Kathy and Curt Marble Cancer Research Fund the Mazumdar-Shaw International Oncology Fellows Program the Burroughs Wellcome
Quidant's research group at ICFO in collaboration with several groups of oncologists joined the worldwide effort devoted to the ultra-sensitive detection of protein markers located on the surface of cancer cells and in peripheral blood
but is used not by oncologists so much because of other side effects. It works by rendering the tumour cells more susceptible to Her-2 inhibitors
Dr. Jonathan Silberstein, Assistant professor of Urology and Chief of Urologic Oncology at Tulane, says of the technology,
"said Neil Spector, an oncologist at Duke Medicine familiar with the work.""But it's not just the increase in clinical efficacy
An international team of researchers, led by Dr Munitta Muthana from the University of Sheffield's Department of Oncology,
'said lead author Dr Nicholas Turner, a Consultant Medical Oncologist at the Royal Marsden NHS Foundation Trust.
and Lora S. Lurie Professor in Medicine-Hematology/Oncology and Biochemistry and Molecular genetics, and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Baylor pediatrician Michele Redell and MD Anderson oncologist David Tweardy appears this week in the journal Angewandte Chemie.
a pediatric hematologist/oncologist at Dana-Farber/Boston Children. ur goal was to break the enhancer,
a leader of Dana-Farber/Boston Children who serves as chairman of pediatric oncology at the Dana-Farber Cancer Institute
and associate chief of hematology/oncology at Boston Children Hospital. t a very different approach to treating disease. he data provide proof of principle that targeted edits to BCL11A enhancer in blood stem cells could be an attractive approach
Mary Lou Smith, a breast cancer survivor and advocate who helped design the trial for ECOG, the Eastern Cooperative Oncology Group,
Results from both studies will be presented at the 51st Annual Meeting of the American Society of Clinical Oncology ASCO).
And from a clinical point of view, this approach could help assist patients and their oncologists in making treatment decisions.""
"said study leader David T. Teachey, M d.,a physician-researcher in hematology and oncology at The Children's Hospital of Philadelphia (CHOP)."
This study utilized 36 well-characterized melanoma cell lines assembled by the MGH Center for Molecular Therapeutics to test all possible combinations of more than 100 oncology drugs,
and do not in others is one of the top goals of oncology, and also one of the oldest. 126 years ago, The british physician, Stephen Paget, formulated his'seed and soil theory,
says Cornelia Trimble, professor of gynecology and obstetrics, oncology, and pathology at Johns hopkins university School of medicine. vaccine able to cure precancerous lesions could eventually be one way women can avoid surgery that is invasive
Professor of Hematology/Oncology at the University of Chicago, there are just not enough players in the generic specialty drug market that have the capability to manufacture these drugs.
Conti and her team studied the launch price of new oncology drugs from 1996 to 2012.
a pediatric oncologist at Fred Hutchinson and the senior author of the CIVO report, published today (April 22) in the journal Science Translational Medicine.
"said Neil Spector, an oncologist at Duke Medicine familiar with the work.""But it's not just the increase in clinical efficacy
"said Dr. Inoel Rivera, a urologic oncologist at Florida Hospital Cancer Institute, which collaborated with Huo on the recent pilot studies."
and an associate professor in the Division of Hematology-Oncology at the U-M Medical school.""Leukemia is a cancer of the body's blood-forming tissues,
The findings were published recently in the journal Gynecologic Oncology. Endometrial cancer of the uterus is the most common form of gynecologic cancer in Europe and North america.
and oncologists at an early stage will be able--unlike today--to predict whether a patient should expect spreading
which patients the most,"says Henrik Schmidt, consultant at the Department of Oncology at Aarhus University Hospital,
standard of care laboratory testing for breast cancer,"says lead author Kim M. Hirshfield, MD, Phd, breast medical oncologist at the Cancer Institute and assistant professor of medicine at Rutgers
and have been an area of recent and intense interest among oncologists. Since 2010, the FDA has approved vaccines and other immunotherapy drugs for melanoma, prostate cancer, and lung cancer.
"In cancer, cachexia also increases your risk of developing toxicity from chemotherapy and other oncological treatments, such as surgery and radiotherapy.
but also allow them to better tolerate their oncological treatments, to stay at home for a longer period of time,
who is Associate professor of Medicine at Harvard Medical school and Clinical Director and Kidney Cancer Center Director at The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute,
and oncologists at an early stage will be able unlike today to predict whether a patient should expect spreading
which patients the most, says Henrik Schmidt, consultant at the Department of Oncology at Aarhus University Hospital,
Clinical Director of the Cancer Research UK/Medical Research Council Oxford Institute for Radiation Oncology, said:
Shannon Maude MD Phd an assistant professor of Pediatrics and a pediatric oncologist at CHOP and Noelle Frey MD MSCE an assistant professor of Medicine and an oncologist at Penn's Abramson's Cancer Center
and create a more uniform shape that we can distribute the dose of radiation through evenly said White director of Breast Radiation Oncology at the Stefanie Spielman Comprehensive Breast Center.
and an associate professor of medicine in the division of hematology and oncology at the David Geffen School of medicine at UCLA. Kitchen and his colleagues were the first to report the use of an engineered molecule called a chimeric antigen receptor,
The study first author was Anjie Zhen, a postdoctoral fellow at UCLA in the Division of Hematology/Oncology, the UCLA AIDS Institute and the Broad Stem Cell Research center.
which is published in the Journal of Clinical Oncology, included 436 patients, all of whom had aggressive, inoperable malignant melanoma.
Alan Melcher, professor of clinical oncology and biotherapy at the University of Leeds, and an expert in oncolytic viruses, said the field had accelerated quickly in recent years."
which is published in the Journal of Clinical Oncology, included 436 patients, all of whom had aggressive, inoperable malignant melanoma.
Alan Melcher, professor of clinical oncology and biotherapy at the University of Leeds, and an expert in oncolytic viruses, said the field had accelerated quickly in recent years."
The findings were announced by Tata Memorial Centre's Dr Anil D'Cruz at an ongoing meeting of American Society of Clinical Oncology at Chicago on May 31.
The findings were announced by Tata Memorial Centre's Dr Anil D'Cruz at an ongoing meeting of American Society of Clinical Oncology at Chicago on May 31.
which have been shown to be very effective in radiation oncology because they break cancer cellsdna into pieces.
you get this big flux of low energy electrons coming out. he finding suggests a new avenue for radiation oncology:
. the Gary Jobson Professor in Medical Oncology at the University of Maryland School of medicine. ur findings provide a strong foundation for further research in the field of cellular immunotherapy for myeloma to help achieve even better
Dr. Elsken van der Wall, a medical oncologist working for the UMC Utrecht Cancer Center e
from oncological research to education. This latest collaboration makes Watson somewhat more tangible to the average person,
to help oncologists find targeted diagnoses. In each of these cases, Watson reads and understands more and more of the published literature
Telomerase is an almost universal oncology target, yet there are few telomerase-directed therapies in human clinical trials,
when oncologists at Memorial Sloan-Kettering Cancer Center (MSK) refused to prescribe Zaltrap (ziv-aflibercept) for metastatic colorectal cancer due to its initial $11, 000-per-month cost.
associate dean of oncology programs at UT Southwestern Medical center and co-author on the current study.""We propose that SW033291 will be useful in accelerating recovery of bone marrow cells following a bone marrow transplant
. professor of molecular and cellular oncology at MD Anderson Cancer Center. ut exactly how this occurs has not been understood fully.
The findings were published in the Journal of Clinical Oncology y
#Ballistic wallpaper to help protect soldiers seeking temporary shelter It sounds like an old Goon Show joke,
A team of oncologists and engineers from the University of Michigan teamed up to help understand this crucial question.
"says co-senior study author Sofia D. Merajver, M d.,Ph d.,scientific director of the breast oncology program at the University of Michigan Comprehensive Cancer Center.
according to Jonathan Schneck, M d.,Ph d.,a professor of pathology, medicine and oncology at the Johns hopkins university School of medicine's Institute for Cell Engineering."
A team of oncologists and engineers from the University of Michigan teamed up to help understand this crucial question.
"says co-senior study author Sofia D. Merajver, M d.,Ph d.,scientific director of the breast oncology program at the University of Michigan Comprehensive Cancer Center.
neuroscience and oncology at the Johns hopkins university School of medicine and the clinical leader of the research team. e think optical coherence tomography has strong potential for helping surgeons know exactly where to cut.
The study was is published in the Journal of Clinical Oncology and included 436 patients all of whom had aggressive malignant melanoma.
which were presented at the American Society of Clinical Oncology. Lung cancer, which is also known as carcinoma of the lung,
"said Dr. Alfredo Quinones-Hinojosa, a professor of neurosurgery, neuroscience and oncology at the Johns hopkins university School of medicine and the clinical leader of the research team."
According to the study, published in The Journal of Clinical Oncology, of the 436 patients with inoperable melanoma, 16.3 percent of them were still in remission six months after the treatment,
an oncologist from Case Western Reserve University in the US, said in a press release.""We have developed a drug that acts like a vitamin for tissue stem cells,
surgical oncologist David Linehan from the University of Rochester Medical centre in the US told Elaine Schattner at Forbes. The key to the new blood test is a tiny,
and the existing American Joint Committee on Cancer pathologic TNM staging system giving transplant physicians and oncologists more information to work with in deciding how often to monitor for recurrence and whether or not adjuvant treatment
. Ruth Tuttle Freeman Research Professor of radiation oncology and radiology and co-director of the Center for Molecular Imaging at the University of Michigan Medical school. ub1 is well-known for its role in cell division.
Linzhao Cheng Ph d. a professor of medicine and oncology in the Johns hopkins university School of medicine; and their colleagues pitted CRISPR against TALEN in human ipscs adult cells reprogrammed to act like embryonic stem cells.
The researchers reported similar results in a study of breast cancer at the 2013 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
the Breast cancer Risk Assessment Tool (BCRAT), are published in the Journal of Clinical Oncology.""Physicians routinely perform biopsies to evaluate concerning findings in the breast,
Joining forces with dermatologists and oncologists from the University Hospital in Zurich and backed by the University Research Priority Program"Translational Cancer Research,
Edward Levine, M d.,Surgical Sciences Oncology; Frank Marini, Ph d, . and Graca Almeida Porada, M d.,Ph d.,Institute for Regenerative medicine;
'said Andrew Berchuck, M d.,director of gynecologic oncology at Duke university Cancer Institute, and senior author of the study.'
The research was conducted as part of the Collaborative Oncological Gene-environment Study (COGS), launched in 2009 with the goal of determining risks of breast, ovarian and prostate cancer.'
. a Mayo Clinic oncologist and lead author of the study.""We believe we have identified a mechanism that seizes the cancer's biological engine
The collaborators include colleagues from the Johns hopkins university School of medicine Departments of Neurosurgery, Oncology, Ophthalmology, and Pathology,
"says Karen Knudsen, Ph d.,Director of the Sidney Kimmel Cancer Center at Thomas Jefferson University, the Hilary Koprowski Professor and Chair of Cancer Biology, Professor of Urology, Radiation Oncology,
and Medical Oncology at Jefferson. Metastasis is thought of as the last stage of cancer. The tumor undergoes a number of changes to its DNA--mutations--that make the cells more mobile
and developed,"says Josep Tabernero, Head of the Medical Oncology Department of Hospital Universitario Vall d'Hebron, Director of VHIO,
and is rapidly gaining importance and momentum in the oncology field. Liquid biopsy, also known as a blood-based biomarker test, is a fast, simple method for detecting RAS (KRAS and NAS) mutation status in tumors
It represents one more important step in realizing the true promise of precision medicine in oncology--the main focus behind research at VHIO which aims to both advance
oncologists were able to use a 3d-printed model that mimics the density of organs in a patient body,
a mark oncologists often use as a proxy for cure in immunotherapy. Importantly, responses to treatment were pronounced most in patients with less advanced cancers (stage IIIB, IIIC,
and is published in the Journal of Clinical Oncology. T-VEC is modified a form of herpes simplex virus type-1
The results of the findings were published recently in the Journal of Clinical Oncology. Uofl was one of the major sites for the phase III clinical trial involving 436 patients who received the viral immunotherapy, talimogene laherparepvec (T-VEC.
More Researchthe Journal of Clinical Oncology report comes on the heels of Chesney findings from another study published this month in the New england Journal of Medicine.
Led by Shigeki Miyamoto, a professor of oncology at UW-Madison, and David Beebe, the John D. Macarthur Professor and Claude Bernard professor of biomedical engineering at UW-Madison, the researchers published news of the advance May 1, 2015, in the Royal Society
the Ingalls Professor of Cancer Genetics at the university School of medicine and a medical oncologist at University Hospitals Case Medical center Seidman Cancer Center. e have developed a drug that acts like a vitamin for tissue stem cells,
as well as the Asa and Patricia Shiverick-Jane Shiverick (Tripp) Professor of Hematological Oncology. Case Western Reserve research associate Amar Desai, Phd, worked between the Markowitz
neuroscience and oncology at the Johns hopkins university School of medicine and the clinical leader of the research team. e think optical coherence tomography has strong potential for helping surgeons know exactly where to cut.
said Dr. Wen H. Shen, the study lead investigator and an assistant professor of cell biology in radiation oncology at Weill Cornell. ased on our research,
Since 2012 the oncological guidelines prescribe that doctors have to choose an individualized approach, where the risk of recurrence of the disease in a specific patient has to determine the follow-up course of action.
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011